Panacea Biotec Limited-Product Pipeline Review-2015

Panacea Biotec Limited-Product Pipeline Review-2015

  • Products Id :- GMDHC07355CDB
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Panacea Biotec Limited-Product Pipeline Review-2015


Global Markets Direct's, 'Panacea Biotec Limited-Product Pipeline Review-2015', provides an overview of the Panacea Biotec Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Panacea Biotec Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Panacea Biotec Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Panacea Biotec Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Panacea Biotec Limited's pipeline products

Reasons To Buy

Evaluate Panacea Biotec Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Panacea Biotec Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Panacea Biotec Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Panacea Biotec Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Panacea Biotec Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Panacea Biotec Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Panacea Biotec Limited Snapshot 7

Panacea Biotec Limited Overview 7

Key Information 7

Key Facts 7

Panacea Biotec Limited-Research and Development Overview 8

Key Therapeutic Areas 8

Panacea Biotec Limited-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Combination Treatment Modalities 14

Panacea Biotec Limited-Pipeline Products Glance 15

Panacea Biotec Limited-Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Panacea Biotec Limited-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Panacea Biotec Limited-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Panacea Biotec Limited-Drug Profiles 20

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Nucovac 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

polio [sabin] vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

PBL-1427 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

bevacizumab biosimilar 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

cetuximab biosimilar 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

darbepoetin alfa 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

etanercept biosimilar 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

hepatitis-B vaccine 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Japanese encephalitis vaccine 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

omalizumab biosimilar 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Peptide for Alopecia 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

rituximab biosimilar 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

trastuzumab biosimilar 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

dengue (tetravalent) vaccine 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

influenza vaccine 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

meningococcal polysaccharide vaccine 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

pertussis (acellular) vaccine 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

pneumococcal vaccine 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Recombinant Protein for Renal Anemia 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

respiratory syncytial virus vaccine 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Synthetic Peptides to Agonize GLP-1 for Type 2 Diabetes 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

yellow fever vaccine 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Panacea Biotec Limited-Pipeline Analysis 44

Panacea Biotec Limited-Pipeline Products by Target 44

Panacea Biotec Limited-Pipeline Products by Route of Administration 45

Panacea Biotec Limited-Pipeline Products by Molecule Type 46

Panacea Biotec Limited-Pipeline Products by Mechanism of Action 47

Panacea Biotec Limited-Recent Pipeline Updates 48

Panacea Biotec Limited-Dormant Projects 49

Panacea Biotec Limited-Company Statement 50

Panacea Biotec Limited-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

Panacea Biotec Limited, Key Information 7

Panacea Biotec Limited, Key Facts 7

Panacea Biotec Limited-Pipeline by Indication, 2015 9

Panacea Biotec Limited-Pipeline by Stage of Development, 2015 12

Panacea Biotec Limited-Monotherapy Products in Pipeline, 2015 13

Panacea Biotec Limited-Combination Treatment Modalities in Pipeline, 2015 14

Panacea Biotec Limited-Phase III, 2015 15

Panacea Biotec Limited-Phase II, 2015 16

Panacea Biotec Limited-Phase I, 2015 17

Panacea Biotec Limited-Preclinical, 2015 18

Panacea Biotec Limited-Discovery, 2015 19

Panacea Biotec Limited-Pipeline by Target, 2015 44

Panacea Biotec Limited-Pipeline by Route of Administration, 2015 45

Panacea Biotec Limited-Pipeline by Molecule Type, 2015 46

Panacea Biotec Limited-Pipeline Products by Mechanism of Action, 2015 47

Panacea Biotec Limited-Recent Pipeline Updates, 2015 48

Panacea Biotec Limited-Dormant Developmental Projects,2015 49

Panacea Biotec Limited, Other Locations 51

Panacea Biotec Limited, Subsidiaries 52

List of Figures

Panacea Biotec Limited-Pipeline by Top 10 Indication, 2015 9

Panacea Biotec Limited-Pipeline by Stage of Development, 2015 12

Panacea Biotec Limited-Monotherapy Products in Pipeline, 2015 13

Panacea Biotec Limited-Combination Treatment Modalities in Pipeline, 2015 14

Panacea Biotec Limited-Pipeline by Top 10 Target, 2015 44

Panacea Biotec Limited-Pipeline by Top 10 Route of Administration, 2015 45

Panacea Biotec Limited-Pipeline by Top 10 Molecule Type, 2015 46

Panacea Biotec Limited-Pipeline Products by Top 10 Mechanism of Action, 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Panacea Biotec Limited; Panacea Biotec Limited - Key Therapeutics; Panacea Biotec Limited - Pipeline Overview and Promising Molecules; Panacea Biotec Limited - News; Panacea Biotec Limited - Latest Updates; Panacea Biotec Limited - Pipeline; Panacea Biotec Limited - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97335
Site License
USD 3000 INR 194670
Corporate User License
USD 4500 INR 292005



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]